Intrabio's Neimann-Pick type C drug is going to be pricey, although it will likely fly under the press' radar like most orphan drug therapies. Those who stand to profit from it hope that will be the case for obvious reasons. So, who's going to cash in on those profits? Mostly venture capitalists and wealthy investors who need more money for awesome things like a swanky condo on the upper east side of NYC.
https://nypost.com/2016/05/26/atlantic-records-ceo-nabs-7m-pad-and-other-news-we-hear/
It's good to know that the horrific, deadly Neimann-Pick type C disease will be beneficial for some fancy people.
https://nypost.com/2016/05/26/atlantic-records-ceo-nabs-7m-pad-and-other-news-we-hear/
It's good to know that the horrific, deadly Neimann-Pick type C disease will be beneficial for some fancy people.